A rare neurological disorder known as Wernicke encephalopathy has been identified in a small number of patients taking GLP-1 drugs for diabetes and weight loss, according to a study published in the journal Clinical Nutrition. Food and Drug Administration adverse event reports and related medical literature between 2023 and 2024 uncovered 15 cases of the potentially life-threatening vitamin B1 deficiency condition among users of the drugs.
Study Findings on GLP-1 Drugs and Wernicke Encephalopathy
Wernicke encephalopathy is a serious neurological disorder triggered by a severe lack of vitamin B1, or thiamine, which can cause permanent memory loss and an inability to form new memories. According to the study findings, 13 of the 15 reported patients experienced severe gastrointestinal manifestations, including significant weight loss, persistent vomiting, loss of appetite, or malnutrition. Vitamin B1 supports the nervous system and brain health and must be obtained entirely through food intake or supplements.
The majority of these adverse event cases involved GLP-1 medications utilizing the active ingredient semaglutide, such as Ozempic and Wegovy, or tirzepatide, such as Zepbound. Approximately 11 percent of U.S. adults, translating to roughly 30 million people, currently take GLP-1 medications for weight loss, according to a Gallup poll conducted in the summer.
Expert Analysis and Clinical Perspective
Medical experts emphasize that while the condition is serious, it remains extremely uncommon given the massive patient population using these therapies. Karthik Achari, a Chicago-based clinician who was not involved in the research, noted to Fox News Digital that researchers found only 15 cases out of millions of active prescriptions, describing the reaction as rare but real.
Researchers and clinicians caution that adverse event reports submitted to the FDA cannot definitively prove that the GLP-1 medications directly caused Wernicke encephalopathy. Additional clinical research is required to establish causation, and scientists stress that patients should not discontinue prescribed treatments based solely on these preliminary findings. Previous investigations have similarly documented links between a small subset of GLP-1 users and the brain condition amidst severe gastroparesis and persistent vomiting, as noted in April research by Dr. Manar Kadhem from Egypt’s Mansoura University.
Medical Response and Treatment Guidelines
Healthcare providers highlight that immediate medical intervention is critical if symptoms of thiamine deficiency emerge in patients experiencing intense gastrointestinal side effects from weight loss therapies. The Cleveland Clinic explains that emergency treatment with thiamine is essential to relieve symptoms and prevent permanent damage to memory and other essential brain functions.
Related reading